{"id":497784,"date":"2020-07-22T15:58:01","date_gmt":"2020-07-22T15:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=497784"},"modified":"2020-07-22T15:58:01","modified_gmt":"2020-07-22T15:58:01","slug":"alzheimers-disease-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-market-size-share-trends-epidemiology-forecast-till-2030_497784.html","title":{"rendered":"Alzheimer’s Disease Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Alzheimer's<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Alzheimer’s disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Alzheimer’s disease attacks the cells of the brain and neurotransmitters, affecting the way brain functions, memory and behaviour. There is no known cure for the disease, and current approaches focus on helping people maintain mental function, manage behavioural symptoms, and slow down specific problems, such as memory loss. Two categories of drugs are approved for Alzheimer’s disease treatment: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.<\/span><\/p>\n

 <\/p>\n

Key benefits of Alzheimer’s disease market report<\/span><\/span><\/a><\/p>\n


<\/a>1. Alzheimer’s Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer’s Disease epidemiology and Alzheimer’s Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Alzheimer’s Disease market report provides insights into the current and emerging therapies.<\/span>
3. Alzheimer’s Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Alzheimer’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer’s Disease market.<\/span><\/span><\/p>\n

 <\/p>\n

Request for sample pages<\/a><\/p>\n

 <\/p>\n

Cholinesterase inhibitors act by increasing the level of acetylcholine; a chemical used by nerve cells to communicate with each other and is vital for learning, memory, and cognitive functions. Of this category, three drugs: Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne) are FDA-approved for the treatment of Alzheimer’s disease and are used to treat mild-to-moderate Alzheimer’s (donepezil can be used for severe Alzheimer’s as well). Donepezil can be used in all stages of Alzheimer disease. Galantamine and rivastigmine are approved for treatment in mild-to-moderate Alzheimer disease only. Donepezil and galantamine are rapid, reversible inhibitors of acetylcholinesterase. Rivastigmine is a slow, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. Most common side effects of cholinesterase inhibitors are gastrointestinal-like nausea, vomiting, and diarrhoea.<\/p>\n


Partial N-Methyl D-aspartate (NMDA) antagonist includes memantine. Memantine (Namenda) is used to treat moderate-to-severe Alzheimer’s disease. However, these drugs do not change the underlying disease process. They are useful for some but not all people and may help only for a limited time. The FDA has also approved Aricept and Namzaric, a combination of Namenda and Aricept, for the treatment of moderate-to-severe Alzheimer’s disease. Dizziness, body aches, headache, and constipation are common side effects. It can be taken in combination with cholinesterase inhibitors.<\/span><\/span><\/span><\/p>\n

 <\/p>\n

Request for sample pages<\/a><\/span><\/span><\/span><\/p>\n

 <\/p>\n

Table of contents<\/span><\/p>\n

1. Report Introduction<\/span><\/p>\n

2. Alzheimer’s Disease Market Overview at a Glance<\/span><\/p>\n

3. Alzheimer’s Disease Disease Background and Overview<\/span><\/p>\n

4. Alzheimer’s Disease Epidemiology and Patient Population<\/span><\/p>\n

5. Epidemiology of Alzheimer’s Disease by Countries (2017–2030)<\/span><\/p>\n

5.1. United States- Epidemiology (2017–2030)<\/span><\/p>\n

5.2. EU-5 – Epidemiology (2017–2030)<\/span><\/p>\n

5.2.1. Assumptions and Rationale<\/span><\/p>\n

5.2.2. Germany<\/span><\/p>\n

5.2.3. France<\/span><\/p>\n

5.2.4. Italy<\/span><\/p>\n

5.2.5. Spain<\/span><\/p>\n

5.2.6. United Kingdom<\/span><\/p>\n

5.3. Japan<\/span><\/p>\n

6. Alzheimer’s Disease Treatments & Medical Practices<\/span><\/p>\n

7. Alzheimer’s Disease Marketed Products<\/span><\/p>\n

7.1. Aricept: Eisai<\/span><\/p>\n

7.2. Exelon: LTS Lohmann Therapie-Systeme\/Novartis<\/span><\/p>\n

7.3. Oligomannate: Green Valley Pharmaceuticals<\/span><\/p>\n

8. Alzheimer’s Disease Emerging Therapies<\/span><\/p>\n

8.1. Key Cross Competition<\/span><\/p>\n

8.2. AGB101: AgeneBio<\/span><\/p>\n

8.3. Bryostatin-1: Neurotrope Bioscience<\/span><\/p>\n

8.4. COR388 HCL: Cortexyme<\/span><\/p>\n

8.5. Eltoprazine: Amarantus Bioscience Holdings<\/span><\/p>\n

8.6. ALZT-OP1: AZ Therapies<\/span><\/p>\n

8.7. Brexpiprazole: Otsuka Pharmaceutical<\/span><\/p>\n

8.8. AKST\/GRF6019: Alkahest<\/span><\/p>\n

8.9. AXS-05: Axsome Therapeutics<\/span><\/p>\n

8.10. Tricaprilin: Cerecin<\/span><\/p>\n

8.11. TRx0237: TauRx Therapeutics<\/span><\/p>\n

8.12. RO7105705: Genentech<\/span><\/p>\n

8.13. Azeliragon (TTP488): vTv Therapeutics<\/span><\/p>\n

9. Alzheimer’s Disease Market Size<\/span><\/p>\n

10. 7MM: Country-Wise Market Analysis<\/span><\/p>\n

10.1. United States Market Size<\/span><\/p>\n

10.2. Germany Market Size<\/span><\/p>\n

10.3. France Market Size<\/span><\/p>\n

10.4. Italy Market Size<\/span><\/p>\n

10.5. Spain Market Size<\/span><\/p>\n

10.6. United Kingdom Market Size<\/span><\/p>\n

10.7. Japan Market Size<\/span><\/p>\n

11. Market Drivers<\/span><\/p>\n

12. Market Barriers<\/span><\/p>\n

13. Alzheimer’s Disease Report Methodology<\/span><\/p>\n

14. DelveInsight Capabilities<\/span><\/p>\n

15. Disclaimer<\/span><\/p>\n

16. About DelveInsight<\/span><\/span><\/span><\/span><\/p>\n

 <\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Alzheimer’s disease Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-497784","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=497784"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/497784\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=497784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=497784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=497784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}